transform deal set stage build next pillar growth new pt
invest summari reiter ow increas pt
previous think histor deal set stage next wave
pipelin growth beyond filgotinib updat model new
collabor well updat us filgotinib timelin wrote
earlier link think deal repres best case scenario glpg
up-front cash payment young ow glpg worth
per share alon probabl give much pipelin credit sens
investor base recent convers glpg retain signific econom
pipelin chang filgotinib econom importantli think
signific capit allow glpg leverag strong discoveri
capabl get us excit next come glpg
review model assumpt account term new
collabor chang account up-front cash payment
equiti invest adjust ipf econom deal
previous ipf worth dcf probabl adjust basi
worth increas opex substanti due greater
commerci contribut glpg pay filgotinib updat
us filgotinib launch timelin model late launch vs previous
regulatori updat given earli juli
increas opex forecast glpg account greater contribut
glpg filgotinib phase spend impact partial off-set
fund ipf phase program
model opex eur eur eur versu prior eur
eur eur respect
 tabl standstil think ipf oa toledo
continu offer signific option next year glpg
yet assign credit oa toledo base case success either
would meaning upsid valuat base case assign success
ipf success think could multi-billion dollar product oa
phase data could import catalyst glpg entitl
mileston opt program ipf
futil interim next month depend enrol could
help de-risk phase toledo enter first studi patient later year
disclosur section may found page
valu glpg probabl adjust basi assign discount rate termin growth rate line peer
similar size develop stage
risk includ greater-than-expect competit glpg lead asset filgotinib and/or
unexpect clinic regulatori setback risk specif filgotinib includ
-- lack efficaci phase trial ulcer coliti crohn psoriat arthriti
-- greater-than-expect competit commerci either addit jak inhibitor
novel biolog biosimilar entrant
-- testicular toxic seen pre-clin seen clinic filgotinib
elli merl cantor fitzgerald glpg statement sale book glpg prob royalti glpg prob pipelin revenu glpg prob adj glpg program prob adj usdfilgotinib probabl adjust royalti co-promot franchis prob adj oa prob adj revenu franchis prob adj revenu ad prob adj revenu piplin probabl adj revenu exchang rate revenu mileston reimburs revenu growth cog product adj sale glpg owe cog adjust sale glpg owe cog research develop revenu revenu oper expens oper loss oper marginfair valu re-measur share subscript agreement -- -- net financi financi financi profit loss incom tax ratenet result continu net net incom loss attribut owner ep per weight averag juli
elli merl cantor fitzgerald glpg statement sale book glpg prob royalti glpg prob pipelin revenu glpg prob adj glpg program prob adj usdfilgotinib probabl adjust royalti co-promot franchis prob adj oa prob adj revenu franchis prob adj revenu ad prob adj revenu piplin probabl adj revenu exchang rate revenu mileston reimburs revenu cog product adj sale glpg owe cog adjust sale glpg owe cog research develop revenu revenu oper expens oper loss oper valu re-measur share subscript agreement -- -- net financi financi financi profit loss incom tax result continu net net incom loss attribut owner ep per
elli merl cantor fitzgerald glpg tax paid- stock base chang net work free time valuat discount growth termin pv termin net share market market cap ex adj sale sensit assum sale market cap ex impli market cap cantor fitzgerald research compani report bloomberg factset
figur cantor glpg valuat revenu summari
programprob successpeak glpg filgotinib indic spondyl filgotinib sale fibrosi idiopath pulmonari atop program defin peak sale compani descript
galapago clinical-stag biotechnolog compani compani lead asset filgotinib partner gilead ow cover
young develop varieti diseas inflamm immunolog space rheumatoid arthriti
ulcer coliti crohn among mani other program develop includ wholli own idiopath pulmonari diseas
ipf franchis enter phase
price close jul
analyst primarili respons research report whose name appear front cover certifi view express
research report accur reflect person view subject secur issuer featur report ii part
research analyst compens directli indirectli relat specif recommend view express
research analyst report
invest bank next month cantor fitzgerald and/or affili expect receiv intend seek compens invest bank
servic within next three month compani referenc within report
cantor fitzgerald and/or affili market maker galapago adr
cantor fitzgerald and/or affili market maker gilead scienc inc
overweight/ow analyst expect stock total return stock price appreci plu dividend outperform rel analyst broadli
defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month overweight rate equat buy rate
neutral analyst expect stock total return stock price appreci plu dividend perform line rel analyst broadli
defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month neutral rate equat hold rate
underweight/uw analyst expect stock total return stock price appreci plu dividend under-perform rel analyst
broadli defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month underweight rate equat sell rate
covered/nc cantor fitzgerald provid invest opinion provid research coverag stock
rated/nr current carri rate stock rate estim review nr rate equat overweight
neutral underweight rate thu count calcul percentag subject compani within three categori
cantor fitzgerald provid invest bank servic within previou month
report inform purpos base publicli avail data believ reliabl represent made data
accur complet opinion project contain herein reflect opinion date report subject chang pursuant
cantor fitzgerald polici author report share compani he/sh cover
cantor fitzgerald cantor fitzgerald logo trademark regist trademark cantor fitzgerald secur affili
countri trademark appear herein properti respect owner neither cantor fitzgerald secur affili
associ affili third parti
materi present sole institut commun meant view complet fundament analysi secur
materi may offer recommend strategi shorter term natur materi contain analysi may narrowli focus
may base either pure quantit model uniqu factor market supply/demand factor surround potenti market move
event make invest decis inform view one factor invest decis process past perform
taken indic guarante futur result
disclosur uk investor
